Purpose: The aim of this paper was to assess and compare the effects of intravitreal ranibizumab and bevacizumab on retinal vessel diameter in eyes with neovascular age-related macular degeneration (AMD). Methods: Patients with neovascular AMD who underwent intravitreal injection of either ranibizumab or bevacizumab were included. Noninjected fellow eyes served as a control. The main outcome measures were central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE), and the artery-vein ratio (AVR). Results: In the ranibizumab group, the mean CRAE value decreased significantly at 1 week and 1 month (p = 0.002). The AVR value decreased significantly at 1 month (p = 0.028). CRVE values did not change at 1 week and 1 month (p = 0.083). In the bevacizumab group, the preinjection CRAE, CRVE, and AVR values did not change through the study period (p = 0.128, p = 0.600, and p = 0.734, respectively). Conclusion: These results suggest that intravitreal ranibizumab led to significant retinal arteriolar vasoconstriction in eyes with neovascular AMD.

1.
Bourne RR, Jonas JB, Flaxman SR, Keeffe J, Leasher J, Naidoo K, et al: Prevalence and causes of vision loss in high-income countries and in Eastern and Central Europe: 1990-2010. Br J Ophthalmol 2014;98:629-638.
2.
Bunce C, Wormald R: Leading causes of certification for blindness and partial sight in England and Wales. BMC Public Health 2006;6:58.
3.
Wong TY, Chakravarthy U, Klein R, Mitchell P, Zlateva G, Buggage R, et al: The natural history and prognosis of neovascular age-related macular degeneration: a systematic review of the literature and meta-analysis. Ophthalmology 2008;115:116-126.
4.
Berg K, Pedersen TR, Sandvik L, Bragadottir R: Comparison of ranibizumab and bevacizumab for neovascular age-related macular degeneration according to LUCAS treat-and-extend protocol. Ophthalmology 2015;122:146-152.
5.
IVAN Study Investigators, Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Wordsworth S, et al: Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN randomized trial. Ophthalmology 2012;119:1399-1411.
6.
Marneros AG, Fan J, Yokoyama Y, Gerber HP, Ferrara N, Crouch RK, et al: Vascular endothelial growth factor expression in the retinal pigment epithelium is essential for choriocapillaris development and visual function. Am J Pathol 2005;167:1451-1459.
7.
Nishijima K, Ng YS, Zhong L, Bradley J, Schubert W, Jo N, et al: Vascular endothelial growth factor-A is a survival factor for retinal neurons and a critical neuroprotectant during the adaptive response to ischemic injury. Am J Pathol 2007;171:53-67.
8.
Tilton RG, Chang KC, Lejeune WS, Stephan CC, Brock TA, Williamson JR: Role for nitric oxide in the hyperpermeability and hemodynamic changes induced by intravenous VEGF. Invest Ophthalmol Vis Sci 1999;40:689-696.
9.
Mulcahy MF, Benson AB 3rd: Bevacizumab in the treatment of colorectal cancer. Expert Opin Biol Ther 2005;5:997-1005.
10.
Kelkar A, Shah R, Kelkar J, Kelkar S, Bhirud S, Gandhi P: Changes in the retinal vascular network morphology(diameter and tortuosity) after administration of intravitreal bevacizumab in a patient with ischaemic branch retinal vein occlusion. Case Rep Ophthalmol 2014;5:411-415.
11.
Micieli JA, Tsui E, Lam WC, Brent MH, Devenyi RG, Hudson C: Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration. Acta Ophthalmol 2012;90:e13-e20.
12.
Wong TY, Knudtson MD, Klein R, Klein BE, Meuer SM, Hubbard LD: Computer-assisted measurement of retinal vessel diameters in the Beaver Dam Eye Study: methodology, correlation between eyes, and effect of refractive errors. Ophthalmology 2004;111:1183-1190.
13.
Knudtson MD, Lee KE, Hubbard LD, Wong TY, Klein R, Klein BE: Revised formulas for summarizing retinal vessel diameters. Curr Eye Res 2003;27:143-149.
14.
Hubbard LD, Brothers RJ, King WN, Clegg LX, Klein R, Cooper LS, et al: Methods for evaluation of retinal microvascular abnormalities associated with hypertension/sclerosis in the Atherosclerosis Risk in Communities Study. Ophthalmology 1999;106:2269-2280.
15.
Aslankurt M, Aslan L, Aksoy A, Erden B, Çekiç O: The results of switching between 2 anti-VEGF drugs, bevacizumab and ranibizumab, in the treatment of neovascular age related macular degeneration. Eur J Ophthalmol 2013;23:553-557.
16.
CATT Research Group, Martin DF, Maguire MG, Ying GS, Grunwald JE, Fine SL, Jaffe GJ: Ranibizumab and bevacizumab for neovascular age-related macular degeneration. N Engl J Med 2011;364:1897-1908.
17.
Hwang DJ, Kim YW, Woo SJ, Park KH: Comparison of systemic adverse events associated with intravitreal anti-VEGF injection: ranibizumab versus bevacizumab. J Korean Med Sci 2012;27:1580-1585.
18.
Kodjikian L, Souied EH, Mimoun G, Mauget-Faÿsse M, Behar-Cohen F, Decullier E, Huot L, et al; GEFAL Study Group: Ranibizumab versus bevacizumab for neovascular age-related macular degeneration: results from the GEFAL noninferiority randomized trial. Ophthalmology 2013;120:2300-2309.
19.
Mendrinos E, Mangioris G, Papadopoulou DN, Donati G, Pournaras CJ: Long-term results of the effect of intravitreal ranibizumab on the retinal arteriolar diameter in patients with neovascular age-related macular degeneration. Acta Ophthalmol 2013;91:e184-e190.
20.
Micieli JA, Tsui E, Lam WC, Brent MH, Devenyi RG, Hudson C: Retinal blood flow in response to an intravitreal injection of ranibizumab for neovascular age-related macular degeneration. Acta Ophthalmol 2012;90:e13-e20.
21.
Pekel G, Acer S, Çetin EN, Yağci R, Kaşikci A, Çevik A: Ocular pulse amplitude and retinal vessel caliber changes after intravitreal ranibizumab. Int Ophthalmol 2015;35:657-662.
22.
Wickremasinghe SS, Guymer RH, Wong TY, Kawasaki R, Wong W, Qureshi S: Retinal venular calibre dilatation after intravitreal ranibizumab treatment for neovascular age-related macular degeneration. Clin Experiment Ophthalmol 2012;40:59-66.
23.
Fontaine O, Olivier S, Descovich D, Cordahi G, Vaucher E, Lesk MR: The effect of intravitreal injection of bevacizumab on retinal circulation in patients with neovascular macular degeneration. Invest Ophthalmol Vis Sci 2011;52:7400-7405.
24.
Tatlipinar S, Dinc UA, Yenerel NM, Gorgun E: Short-term effects of a single intravitreal bevacizumab injection on retinal vessel calibre. Clin Exp Optom 2012;95:94-98.
25.
Hosseini H, Lotfi M, Esfahani MH, Nassiri N, Khalili MR, Razeghinejad MR, Nouri-Mahdavi K: Effect of intravitreal bevacizumab on retrobulbar blood flow in injected and uninjected fellow eyes of patients with neovascular age-related macular degeneration. Retina 2012;32:967-971.
26.
Bonnin P, Pournaras JA, Lazrak Z, Cohen SY, Legargasson JF, Gaudric A, Levy BI, Massin P: Ultrasound assessment of short-term ocular vascular effects of intravitreal injection of bevacizumab (Avastin[®]) in neovascular age-related macular degeneration. Acta Ophthalmol 2010;88:641-645.
27.
Mete A, Saygili O, Mete A, Bayram M, Bekir N: Effects of intravitreal bevacizumab (Avastin®) therapy on retrobulbar blood flow parameters in patients with neovascular age-related macular degeneration. J Clin Ultrasound 2010;38:66-70.
28.
Chan CK, Jain A, Sadda S, Varshney N: Optical coherence tomographic and visualresults at six months after transitioning to aflibercept for patients on prior ranibizumab or bevacizumab treatment for exudative age-related macular degeneration (an American Ophthalmological Society thesis). Trans Am Ophthalmol Soc 2014;112:160-198.
29.
Wang W, Zhang X: Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis. PLos One 2014;9:e109744.
30.
Matsuyama K, Ogata N, Matsuoka M, Wada M, Takahashi K, Nishimura T: Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab. Br J Ophthalmol 2010;94:1215-1218.
31.
Rouvas A, Liarakos VS, Theodossiadis P, Papathanassiou M, Petrou P, Ladas I, Vergados I: The effect of intravitreal ranibizumab on the fellow untreated eye with subfoveal scarring due to exudative age-related macular degeneration. Ophthalmologica 2009;223:383-389.
32.
Bakbak B, Ozturk BT, Gonul S, Yilmaz M, Gedik S: Comparison of the effect of unilateral intravitreal bevacizumab and ranibizumab injection on diabetic macular edema of the fellow eye. J Ocul Pharmacol Ther 2013;29:728-732.
33.
Klein R, Klein BE, Tomany SC, Wong TY: The relation of retinal microvascular characteristics to age-related eye disease: the Beaver Dam eye study. Am J Ophthalmol 2004;137:435-444.
34.
Chin YC, Wong TY, Cheung CMG: Retinal vascular caliber and age-related macular degeneration in an Indian population from Singapore. Ophthalmic Epidemiol 2014;21:224-229.
35.
Ikram MK, van Leeuwen R, Vingerling JR, Hofman A, de Jong PT: Retinal vessel diameters and the risk of incident age-related macular disease: the Rotterdam Study. Ophthalmology 2005;112:548-552.
36.
Jeganathan VS, Kawasaki R, Wang JJ, Aung T, Mitchell P, Saw SM, Wong TY: Retinal vascular caliber and age-related macular degeneration: the Singapore Malay Eye Study. Am J Ophthalmol 2008;146:954-959.
37.
Yang K, Zhan SY, Liang YB, Duan X, Wang F, Wong TY, Sun LP, Wang NL: Association of dilated retinal arteriolar caliber with early age-related macular degeneration: the Handan Eye Study. Graefes Arch Clin Exp Ophthalmol 2012;250:741-749.
38.
Chen E, Hsu J, Park CH: Acute visual acuity loss following intravitreal bevacizumab for diabetic macular edema. Ophthalmic Surg Laseres Imaging 2008;40:68-70.
39.
Kim KS, Chang HR, Song S: Ischaemic change after intravitreal bevacizumab (Avastin) injection for macular oedema secondary to non-ischaemic central retinal vein occlusion. Acta Ophthalmol 2008;86:925-927.
40.
Lee CS, Koh HJ: Multiple retinal haemorrhages in diabetic retinopathy after adjunctive intravitreal bevacizumab (Avastin®) with pars plana vitrectomy. Acta Ophthalmol 2008;86:812-813.
41.
Yokoyama K, Choshi T, Kimoto K, Shinoda K, Nakatsuka K: Retinal circulatory disturbances following intracameral injection of bevacizumab for neovascular glaucoma. Acta Ophthalmol 2008;86:927-928.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.